
Site burden is now measured through satisfaction surveys, in-the-moment check-ins, and adoption patterns, but each method catches a different moment, and the gaps between them decide whether teams can act before burden becomes risk.
ACM Global Laboratories, Inc. has announced the rebranding of ABS Laboratories to ACM Bioanalytical Services.
Founded over two decades ago by Drs. Colin Feyerabend and Mira Doig, ABS Laboratories was purchased by ACM Global Laboratories in 2018 as it expanded its central laboratory testing offerings for clinical trials to include bioanalytical services. ABS Laboratories, now ACM Bioanalytical Services, specializes in complex assay development and validation for the quantification of drugs, metabolites and biomarkers in biological samples used in pharmaceutical research and development.
ACM Bioanalytical Services will maintain all of its employees, equipment, and location in York, UK.






